Literature DB >> 26005521

Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation.

Fabio Del Bello1, Valentina Bargelli2, Carlo Cifani3, Paola Gratteri4, Carla Bazzicalupi5, Eleonora Diamanti1, Mario Giannella1, Valerio Mammoli1, Rosanna Matucci2, Maria Vittoria Micioni Di Bonaventura3, Alessandro Piergentili1, Wilma Quaglia1, Maria Pigini1.   

Abstract

Pharmacological studies have suggested that I1-imidazoline receptors are involved in the regulation of cardiovascular function and that selective I1-agonists, devoid of the side effects associated with the common hypotensive α2-adrenoreceptor agonists, might be considered as a second generation of centrally acting antihypertensives. Therefore, in the present study, inspired by the antihypertensive behavior of our selective I1-agonist 4, we designed, prepared, and studied the novel analogues 5-9. A selective I1-profile, associated with significant hemodinamic effects, was displayed by 5, 8, and 9. Interestingly, the highest potency and longest lasting activity displayed by 8 (carbomethyline) suggested that van der Waals interactions, promoted by the ortho methyl decoration of its aromatic moiety, are particularly advantageous. In addition, in analogy to what was noted for (S)-(+)-4, the observation that only (S)-(+)-8 displayed significant hemodynamic effects unequivocally confirmed the stereospecific nature of the I1 proteins.

Entities:  

Keywords:  I1-agonists; antihypertensive agents; bradicardic agents; carbomethyline; imidazoline compounds; stereoselectivity

Year:  2015        PMID: 26005521      PMCID: PMC4434467          DOI: 10.1021/acsmedchemlett.5b00115

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  25 in total

1.  Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.

Authors:  Francesco Gentili; Claudia Cardinaletti; Cristian Vesprini; Antonio Carrieri; Francesca Ghelfi; Aniket Farande; Mario Giannella; Alessandro Piergentili; Wilma Quaglia; Jonne M Laurila; Anna Huhtinen; Mika Scheinin; Maria Pigini
Journal:  J Med Chem       Date:  2008-06-25       Impact factor: 7.446

2.  Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?

Authors:  Claudia Cardinaletti; Laura Mattioli; Francesca Ghelfi; Fabio Del Bello; Mario Giannella; Ariana Bruzzone; Hervé Paris; Marina Perfumi; Alessandro Piergentili; Wilma Quaglia; Maria Pigini
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

3.  Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (i1)-receptor-mediated hypotension.

Authors:  Jian Zhang; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2005-05-18       Impact factor: 4.030

4.  alpha 2-adrenoreceptors profile modulation. 2. Biphenyline analogues as tools for selective activation of the alpha 2C-subtype.

Authors:  Francesco Gentili; Francesca Ghelfi; Mario Giannella; Alessandro Piergentili; Maria Pigini; Wilma Quaglia; Cristian Vesprini; Pierre-Antoine Crassous; Hervé Paris; Antonio Carrieri
Journal:  J Med Chem       Date:  2004-12-02       Impact factor: 7.446

5.  Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.

Authors:  A Haenni; H Lithell
Journal:  J Hypertens Suppl       Date:  1999-08

6.  Medetomidine analogs as selective agonists for the human alpha2-adrenoceptors.

Authors:  Shilpa G Lalchandani; Xiaoyang Zhang; Seoung Soo Hong; Stephen B Liggett; Wei Li; Bob M Moore; Duane D Miller; Dennis R Feller
Journal:  Biochem Pharmacol       Date:  2004-01-01       Impact factor: 5.858

7.  Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.

Authors:  Risto Kaaja; Karin Manhem; Jaakko Tuomilehto
Journal:  Int J Clin Pract Suppl       Date:  2004-03

Review 8.  Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.

Authors:  Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  Pharmacol Ther       Date:  2009-04-23       Impact factor: 12.310

9.  Imidazoline binding sites (IBS) profile modulation: key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues.

Authors:  Francesco Gentili; Pascal Bousquet; Livio Brasili; Monique Dontenwill; Josiane Feldman; Francesca Ghelfi; Mario Giannella; Alessandro Piergentili; Wilma Quaglia; Maria Pigini
Journal:  J Med Chem       Date:  2003-05-22       Impact factor: 7.446

10.  A new pyrroline compound selective for I1-imidazoline receptors improves metabolic syndrome in rats.

Authors:  Lyne Fellmann; Véronique Regnault; Hugues Greney; Vincent Gasparik; Adeline Muscat; Jean-Pierre Max; Luc Gigou; Valérie Oréa; Gérard Chetrite; Anne Pizard; Nathalie Niederhoffer; Claude Julien; Patrick Lacolley; Bruno Fève; Pascal Bousquet
Journal:  J Pharmacol Exp Ther       Date:  2013-07-01       Impact factor: 4.030

View more
  4 in total

1.  Imidazoleacetic acid-ribotide in vestibulo-sympathetic pathway neurons.

Authors:  Gay R Holstein; Victor L Friedrich; Giorgio P Martinelli
Journal:  Exp Brain Res       Date:  2016-07-13       Impact factor: 1.972

2.  Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction.

Authors:  Maria Elena Giusepponi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Laura Mattioli; Alan Hudson; Eleonora Diamanti; Fabio Del Bello; Mario Giannella; Valerio Mammoli; Corinne Dalila Paoletti; Alessandro Piergentili; Maria Pigini; Wilma Quaglia
Journal:  ACS Med Chem Lett       Date:  2016-09-08       Impact factor: 4.345

3.  A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus.

Authors:  Valerio Mammoli; Alessandro Bonifazi; Diego Dal Ben; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Maria Pigini; Wilma Quaglia; Ajiroghene Thomas; Amy H Newman; Sergi Ferré; Marta Sanchez-Soto; Thomas M Keck; Fabio Del Bello
Journal:  ChemMedChem       Date:  2016-03-15       Impact factor: 3.466

4.  The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity.

Authors:  Laura Micheli; Lorenzo Di Cesare Mannelli; Fabio Del Bello; Mario Giannella; Alessandro Piergentili; Wilma Quaglia; Donatello Carrino; Alessandra Pacini; Carla Ghelardini
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.